Atria Wealth Solutions Inc. Sells 163 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Atria Wealth Solutions Inc. decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 4.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,712 shares of the medical instruments supplier’s stock after selling 163 shares during the period. Atria Wealth Solutions Inc.’s holdings in West Pharmaceutical Services were worth $1,393,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Cetera Investment Advisers raised its holdings in shares of West Pharmaceutical Services by 4.4% in the first quarter. Cetera Investment Advisers now owns 4,864 shares of the medical instruments supplier’s stock worth $1,998,000 after buying an additional 207 shares during the last quarter. Moors & Cabot Inc. lifted its position in West Pharmaceutical Services by 54.4% during the 1st quarter. Moors & Cabot Inc. now owns 849 shares of the medical instruments supplier’s stock worth $349,000 after acquiring an additional 299 shares during the period. National Pension Service grew its stake in West Pharmaceutical Services by 0.4% during the 1st quarter. National Pension Service now owns 103,190 shares of the medical instruments supplier’s stock valued at $42,381,000 after purchasing an additional 394 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of West Pharmaceutical Services by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,716,312 shares of the medical instruments supplier’s stock worth $3,579,876,000 after purchasing an additional 82,459 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in shares of West Pharmaceutical Services by 152.8% during the first quarter. Baird Financial Group Inc. now owns 4,262 shares of the medical instruments supplier’s stock worth $1,751,000 after purchasing an additional 2,576 shares during the period. Institutional investors and hedge funds own 91.23% of the company’s stock.

West Pharmaceutical Services Stock Performance

WST opened at $409.64 on Monday. The stock has a market cap of $30.31 billion, a P/E ratio of 55.28, a P/E/G ratio of 4.04 and a beta of 1.05. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.70 and a quick ratio of 2.89. The firm has a fifty day moving average price of $358.15 and a 200 day moving average price of $367.59. West Pharmaceutical Services, Inc. has a 1 year low of $264.52 and a 1 year high of $415.73.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 7th. Stockholders of record on Wednesday, January 31st were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.20%. The ex-dividend date of this dividend was Tuesday, January 30th. West Pharmaceutical Services’s payout ratio is currently 10.80%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price target for the stock from $323.00 to $536.00 in a report on Wednesday, February 7th. Stephens decreased their target price on shares of West Pharmaceutical Services from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, October 27th. Finally, StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $412.20.

Check Out Our Latest Analysis on WST

Insider Activity

In other West Pharmaceutical Services news, CAO Chad Winters sold 1,013 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $349.00, for a total transaction of $353,537.00. Following the transaction, the chief accounting officer now owns 1,270 shares in the company, valued at $443,230. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.13% of the company’s stock.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.